Membranous Nephropathy
Conditions
Interventions
treatment group:oral CsA, glucosteroid aInterleukin 2nd
Control group:oral CsA and glucosteroid
Sponsors
Shijiazhuang kidney disease hospital Limited company
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18-70 yrs old, male or female; 2) Membranous nephropathy proved by renal pathology and clinical; 3) 2 times the usual dose of ACEI / ARB treatment for 3 months or more, 24h proteinuria =4g/d and serum albumia =30ml/min;
Exclusion criteria
Exclusion criteria: 1) Secondary membranous nephropathy: secondary to hepatitis B or hepatitis C virus, systemic lupus erythematosus, malignant tumors, heavy metal poisoning caused by membranous nephropathy; 2) Diabetic patients; 3) Active ulcer or gastrointestinal bleeding; 4) Combined with other types of kidney disease; 5) Uncontrolled infection 6) Uncontrolled high blood pressure 7) Combined with autoimmune diseases; 8) Active malignancy; 9) Pregnancy or breastfeeding; 10) Combined with chronic liver disease, or liver enzyme more than 2 times the normal upper limit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urinary protein quantity; | — |
Secondary
| Measure | Time frame |
|---|---|
| regulatory T cells;eGFR;anti-PLA2R; | — |
Countries
China
Contacts
Public ContactYinghui Jiang
Shijiazhuang kidney disease hospital Limited company
Outcome results
None listed